Elanco CEO on Boosted Forecast, Surge in Tick Bites
Speakers
Jeff Simmons
— President and CEO, Elanco Animal Health
Summary
Elanco CEO Jeff Simmons discusses the company's strongest six months since IPO, driven by blockbuster product launches, innovation, and a surge in tick bites boosting demand. He highlights raised guidance, resilient pet health spending, and an omnichannel strategy, painting a bullish outlook for the animal health leader.
- Elanco reported 10% revenue growth and raised full-year guidance.
- US pet health grew 11%, farm animal 11%, cattle 17%, with broad-based strength.
- Zenrelia became a blockbuster with over $100 million in first-half sales.
- Credelio Quattro parasiticide gains share due to differentiated FDA-approved label, fast tick kill, and international launches.
- Monoclonal antibody dermatology treatment sees demand doubling, with supply ramp expected by 2027.
- Tick prevalence is at a multiyear high, driving vet visits and product demand.
- Consumer survey shows over 90% of pet owners maintain or increase spending on innovative pet health.
- Omnichannel strategy captures demand online and in-clinic, leveraging Bayer Animal Health acquisition.
Ideas
Elanco's innovation drives accelerated growth and raised guidance.
Elanco delivered a strong beat-and-raise quarter with 10% reported revenue growth, the best six months since IPO. Raised full-year guidance is driven by all segments: US pet health (+11%), farm animal (+11%), international pet health (+9%), cattle (+17%). Growth is underpinned by differentiated innovation in large animal health markets, including the blockbuster Zenrelia (over $100M in first half) and Credelio Quattro, the only FDA-approved four-active-ingredient parasiticide with faster speed of tick kill, broad coverage, and heartworm protection, launching in Europe, Australia, Japan. The dermatology pipeline monoclonal antibody treatment is seeing demand double expectations, with unconstrained supply expected by 2027. Consumer willingness to spend on innovative pet health remains high even in a volatile economy, and tick prevalence is at a multiyear high driving vet visits. Elanco's omnichannel strategy positions it to capture demand wherever pet owners choose to shop, supporting long-term growth.
Up Next
This Bloomberg Markets video, published August 06, 2026, features Jeff Simmons discussing ELAN. 1 trade idea extracted by AI with direction and confidence scoring.
Speakers: Jeff Simmons · Tickers: ELAN